RayKnowChina Research Map
Shortlist0

RecruitingMultiple myelomaPhase 3

Registered title, quoted from ClinicalTrials.gov

Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

An open trial on multiple myeloma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study sitePeking University People's Hospital北京大学人民医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06514508, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 78 years; sex: all

    Registered eligibility fields

  2. Myocardial infarction, CABG, coronary or cerebral artery stenting and/or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months, Angina Pectoris Class >2 or NYHA Heart Failure Class >2.

    Exclusion criterion 32

  3. Female subjects must be of non-childbearing potential or, if of childbearing potential, must have a negative serum pregnancy test at screening and negative serum pregnancy test within 72 hours prior to G-CSF first administration. Women of childbearing potential (WOCBP) and male subjects with WOCBP partners must agree to use highly effective contraception method during the study period and within 90 days after the last study treatment.

    Inclusion criterion 10

    Is currently participating and/or receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

    Exclusion criterion 28

    Is pregnant or breast feeding or expecting to conceive or women of childbearing potential unless consent to use two contraceptive methods or highly effective contraception, within the projected duration of the trial, starting with the Screening Visit through 90 days after the last dose of study drug.

    Exclusion criterion 36

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

    Inclusion criterion 8

  5. Eltrombopag, romiplostim or platelet stimulating agents: 30 days

    Exclusion criterion 13

  6. Known human immunodeficiency virus (HIV) or active Hepatitis B (e.g., Hepatitis B Surface Antigen [HBsAg] reactive and HBV DNA>500 IU/mL or >2500 copies/mL) or Hepatitis C (e.g., Hepatitis C Virus [HCV] RNA [qualitative] is positive).

    Exclusion criterion 37

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06514508, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • (Limit: 15,000 characters)
  • Patients must have a signed study informed consent prior to entering the study.
  • Patients must be between the ages of 18 and 78 years.
  • Diagnosis of active multiple myeloma (aMM) as defined by IMWG criteria.
  • At least one week (7 days) from last induction cycle of combination/multi-agent chemotherapy (e.g. KRD [carfilzomib, lenalidomide, dexamethasone] or VRD [bortezomib, lenalidomide, dexamethasone]) or from last single agent chemotherapy (e.g. lenalidomide, pomalidomide, bortezomib, dexamethasone, etc) prior to the first dose of G-CSF for mobilization.
  • Eligible for Autologous Hematopoietic stem cell transplantation according to the Investigator's discretion.
  • The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR).
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Adequate organ function at screening.
  • Female subjects must be of non-childbearing potential or, if of childbearing potential, must have a negative serum pregnancy test at screening and negative serum pregnancy test within 72 hours prior to G-CSF first administration. Women of childbearing potential (WOCBP) and male subjects with WOCBP partners must agree to use highly effective contraception method during the study period and within 90 days after the last study treatment.

Exclusion Criteria:

  • Previous history of autologous or allogeneic-HCT.
  • Failed previous HSC collections or collection attempts.
  • Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:
  • Dexamethasone: 7 days
  • Thalidomide: 7 days
  • Lenalidomide: 7 days
  • Pamolidomide: 7 days
  • Bortezomib: 7 days
  • Carfilzomib: 7 days
  • G-CSF: 14 days
  • GM-CSF or Neulasta®: 21 days
  • Erythropoietin or erythrocyte stimulating agents: 30 days
  • Eltrombopag, romiplostim or platelet stimulating agents: 30 days
  • Carmustine (BCNU): 42 days/6 weeks
  • Daratumumab or any other anti-CD38: 28 days
  • Ixazomib: 7 day.
  • Received >6 cycles lifetime exposure to thalidomide or lenalidomide.
  • Received >8 cycles of alkylating agent combinations.
  • Received > 6 cycles of melphalan.
  • Received prior treatment with radioimmunotherapy (e.g. radionuclides).
  • Received prior treatment with venetoclax.
  • Plans to receive maintenance treatment within 60 days post- transplantation (e.g.lenalidomide, bortezomib, pomalidomide, thalidomide, carfilzomib, etc.).
  • Has received a live vaccine within 30 days of the planned start of G-CSF administration. Seasonal flu vaccines that do not contain live virus are permitted.
  • Known active CNS metastases or carcinomatous meningitis.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to motixafortide, G-CSF, or other agents used in the study.
  • Has an active or uncontrolled infection requiring systemic therapy.
  • Has a known additional malignancy that is progressing or requires active treatment.
  • Is currently participating and/or receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
  • O2 saturation < 92% (on room air).
  • Personal history or family history of Long QT Syndrome or Torsade de Pointes.
  • History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden cardiac death.
  • Myocardial infarction, CABG, coronary or cerebral artery stenting and/or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months, Angina Pectoris Class >2 or NYHA Heart Failure Class >2.
  • ECG at screening showing QTcF > 470 msec and/or PR > 280 msec.
  • Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Is pregnant or breast feeding or expecting to conceive or women of childbearing potential unless consent to use two contraceptive methods or highly effective contraception, within the projected duration of the trial, starting with the Screening Visit through 90 days after the last dose of study drug.
  • Known human immunodeficiency virus (HIV) or active Hepatitis B (e.g., Hepatitis B Surface Antigen [HBsAg] reactive and HBV DNA>500 IU/mL or >2500 copies/mL) or Hepatitis C (e.g., Hepatitis C Virus [HCV] RNA [qualitative] is positive).
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.

Quoted from ClinicalTrials.gov, NCT06514508, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06514508, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06514508